Rakuten Medical, Inc. (Rakuten Medical) has elected to discontinue use of the name “Illuminox,” and to start using a new, evolved name “Alluminox™” for our proprietary, anti-cancer, photoimmunotherapy technology platform, which is comprised of drug, medical device, and other related technologies. This name change will take effect globally from April 1, 2022.